NYSE · ELV

Elevance Health, Inc.

$377.68 -$1.63 (-0.43%) 1D After hours

Key Metrics

$82.26B
Market cap
15.69×
P/E · TTM
$200.42B
Revenue · TTM
$5.24B
Net income
EPS · TTM $23.08
Dividend yield 1.8%
Free cash flow $6.45B
Beta · 1Y 0.37
EBITDA · TTM $7.74B
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    The stock moved -8.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 15
  • Mar 2
    The stock moved -8.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$82.26B
Enterprise value$76.70B
Shares outstanding216.9M
52-wk range$273.71 – $436.24
Avg volume · 20D1.4M
Net cash $5.56B
Book value / share$193.23
IndustryHospital & Medical Service Plans
ExchangeNYSE
About Elevance Health, Inc.
IPO dateOct 30, 2001
Employees97100

Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E15.69
P/S0.41
P/FCF12.75
EV/EBITDA9.90
EV/Sales0.38
Graham №$316.75

Profitability

Gross
Operating 3.1%
Net 2.6%
FCF 3.2%
ROE / ROIC 12.3% · 13.3%

Financial Health

Current ratio1.48
Quick ratio
Debt / equity0.71
Debt / EBITDA 4.02
Net cash $5.56B
Working capital$21.72B

Cash Flow · TTM

Operating CF $7.61B
Capex −$1.16B
Free cash flow $6.45B
Buybacks $2.85B
Dividends paid $1.52B
Shareholder yield 5.3%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

3.0
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$316.75 vs $377.68
Trades 1.2× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings